Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock is soaring. August 19, 2026 MMN Editor Filed Under: UncategorizedThe candidate is a combination of an mRNA therapeutic vaccine and Merck’s cancer drug Keytruda.